cardiogenic shock


Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Wikipedia.

cardiogenic shock

[¦kärd·ē·ō¦jen·ik ′shäk]
(medicine)
Shock due to inadequate arterial blood flow following left ventricular failure or pulmonary embolism.
References in periodicals archive ?
Asked by a concerned audience member how physicians who decline to prescribe a beta-blocker for patients with acute coronary syndrome and one or more shock risk factors can avoid taking a hit for noncompliance with a Joint Commission and Medicare core performance indicator, the hospitalist replied that the key is to avoid "early" use of the medication in patients with cardiogenic shock risk factors.
Lactate and glucose metabolism in severe sepsis and cardiogenic shock.
An Overview of Pipeline Products for Cardiogenic Shock
An IABP was implanted due to early cardiogenic shock and the patient was urgently transferred to our institution for primary coronary intervention.
A growing body of research suggests that overproduction of nitric oxide inside heart and blood vessel cells following a heart attack may play a critical role in the development of cardiogenic shock.
2] to predict the status of the cardiac output may be different in patients with cardiogenic shock (ischaemic hypoxia) or septic shock (cytotoxic hypoxia), sensitivity analysis was performed with data from the patients with cardiogenic shock only (17).
We are particularly pleased by receiving this designation in Europe because of the pioneering role European investigators are playing in the development of TAI for the management of cardiogenic shock," said Kenneth E.
A hemodynamic support device is recommended for patients with cardiogenic shock after STEMI who do not quickly stabilize with pharmacological therapy," and "refractory cardiogenic shock unresponsive to revascularization may necessitate institution of more intensive cardiac support with a ventricular assist device or other hemodynamic support devices to allow for myocardial recovery or subsequent cardiac transplantation in suitable patients.
Cardiome intends to initially develop GED-aPC in cardiogenic shock, a life-threatening form of acute circulatory failure due to cardiac dysfunction, which is a leading cause of death for patients hospitalized following a heart attack.
Arginox Pharmaceuticals, an emerging specialty pharmaceutical company, today announced that it has begun patient enrollment in Europe in TRIUMPH, a pivotal Phase III trial of the company's lead investigational drug, Tilarginine Acetate Injection (TAI), for the treatment of cardiogenic shock (CS), one of the most serious complications of a heart attack.